WST Intrinsic Stock Value – Oregon Public Employees Retirement Fund Reduces Stake in West Pharmaceutical Services,
January 30, 2023
Trending News 🌥️
WST Intrinsic Stock Value – West Pharmaceutical Services ($NYSE:WST), Inc. is a leading provider of packaging components and delivery systems for the pharmaceutical and healthcare industries. The company’s products are used by some of the largest pharmaceutical companies in the world and its innovative technology has positioned it as a leader in the field. Despite the recent decrease in OPERF’s stake, West Pharmaceutical Services, Inc. continues to be a valuable investment opportunity and it remains one of the most popular stocks in the healthcare sector.
Share Price
On Friday, West Pharmaceutical Services, Inc. (WEST) stock opened at $256.3 and closed at $259.6, up 1.9% from the previous closing price of 254.8. The move is part of an effort by the OPERF to diversify its investments and reduce risk. The company manufactures rubber and plastics components, drug delivery systems and other products used in a wide range of medical applications. WEST has a global presence with production plants located in North America, Europe and Asia.
Despite the recent reduction in the OPERF’s stake, WEST remains a popular stock among investors. Overall, the reduction of the OPERF’s stake in WEST is not expected to have any significant impact on its stock price or performance. WEST remains an attractive investment opportunity for those looking for long-term growth potential. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for WST. More…
| Total Revenues | Net Income | Net Margin |
| 2.91k | 630.6 | 21.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for WST. More…
| Operations | Investing | Financing |
| 654 | -270.8 | -290.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for WST. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.32k | 846 | 33.39 |
Key Ratios Snapshot
Some of the financial key ratios for WST are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 17.5% | 40.6% | 25.5% |
| FCF Margin | ROE | ROA |
| 13.3% | 18.9% | 14.0% |
VI Analysis – WST Intrinsic Stock Value
The company’s fundamentals give insight into its long term potential and with the help of VI app, it is easier to analyze them. According to the data compiled by VI Line, the intrinsic value of West Pharmaceutical Services share is around $348.6, while it is currently traded at $259.6. This implies that the stock is undervalued by 26%. All these factors make West Pharmaceutical Services an attractive investment option for those looking for long term gains. More…
VI Peers
The company operates in North America, Europe, Asia, and South America. Seikagaku Corp, Shenyang Xingqi Pharmaceutical Co Ltd, and Shenzhen Salubris Pharmaceuticals Co Ltd are all competitors of West Pharmaceutical Services Inc.
– Seikagaku Corp ($TSE:4548)
Seikagaku Corp is a Japanese company that specializes in the research and development of pharmaceuticals. The company has a market cap of 53.35B as of 2022 and a return on equity of 2.38%. Seikagaku Corp’s products include treatments for osteoarthritis, inflammatory diseases, and cancer.
– Shenyang Xingqi Pharmaceutical Co Ltd ($SZSE:300573)
Shenyang Xingqi Pharmaceutical Co Ltd is a pharmaceutical company with a market cap of 10.63B as of 2022. The company has a return on equity of 12.24%. The company’s main products are traditional Chinese medicines and western medicines. The company also has a research and development center which is responsible for the development of new products and the improvement of existing products. The company has a strong marketing network and a good reputation in the industry.
– Shenzhen Salubris Pharmaceuticals Co Ltd ($SZSE:002294)
Shenzhen Salubris Pharmaceuticals Co Ltd is a Chinese pharmaceutical company with a market cap of 37.86B as of 2022. The company’s ROE is 6.05%. Shenzhen Salubris Pharmaceuticals Co Ltd is engaged in the research, development, manufacture and sale of pharmaceutical products. The company’s products include drugs for the treatment of cardiovascular and cerebrovascular diseases, cancer, infections, digestive diseases and other diseases.
Summary
The Oregon Public Employees Retirement Fund recently reduced its stake in West Pharmaceutical Services, Inc., a global provider of components and systems used in injectable drug delivery. This decision reflects a shift in the Fund’s investment strategy and should be seen as a sign that West Pharmaceutical Services is not meeting the Oregon Public Employees Retirement Fund’s expectations for long-term returns. Analysts suggest that investors should take this news into account when considering investments in West Pharmaceutical Services. Before deciding to invest, investors should carefully evaluate the company’s financials and understand the risks associated with the stock.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
